{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:16:38Z","timestamp":1789665398971,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T18:57:58Z","timestamp":1588791478000},"page":"647-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical and Biological Prognostic Factors in Follicular Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Anand A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2020.02.002_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hoc.2020.02.002_bib2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying Non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib3","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib5","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3324\/haematol.12754","article-title":"Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas","volume":"93","author":"Piccaluga","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.002_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.002_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times: clinical significance of grading follicular lymphoma","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3109\/10428194.2013.802778","article-title":"Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy","volume":"55","author":"Wahlin","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2020.02.002_bib10","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.3324\/haematol.2017.175059","article-title":"Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort","volume":"103","author":"Rimsza","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.002_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2001.19.2.420","article-title":"Frequency of the Bcl-2\/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma","volume":"19","author":"Summers","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1200\/JCO.2013.52.8190","article-title":"t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma","volume":"32","author":"Roulland","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2009-01-198580","article-title":"Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations","volume":"114","author":"Leich","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib14","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/blood-2011-06-361972","article-title":"MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype","volume":"118","author":"Leich","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V84.4.1043.1043","article-title":"Prognostic value of chromosomal abnormalities in follicular lymphoma","volume":"84","author":"Tilly","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib16","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/JCO.2002.12.006","article-title":"Clinicopathologic correlations of genomic gains and losses in follicular lymphoma","volume":"20","author":"Viardot","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.15664","article-title":"Prognostic impact of trisomy 21 in follicular lymphoma","volume":"184","author":"Mitsui","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2020.02.002_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2020.02.002_bib21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2018.07.005","article-title":"New concepts in follicular lymphoma biology: from BCL2 to epigenetic regulators and non-coding RNAs","volume":"45","author":"Devan","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.hoc.2020.02.002_bib25","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O\u2019Shea","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.leu.2403802","article-title":"A\u00a0limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"19","author":"Davies","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.02.002_bib27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.02.002_bib28","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.hoc.2020.02.002_bib29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib30","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.002_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2020.02.002_bib32","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2020.02.002_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A\u00a0gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.002_bib36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","article-title":"Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma","volume":"12","author":"L\u00f3pez-Guillermo","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib38","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A\u00a0simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib41","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib42","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","author":"Lockmer","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib43","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib44","first-page":"651","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.hoc.2020.02.002_bib45","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ajh.25493","article-title":"Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma","volume":"94","author":"St-Pierre","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib47","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib48","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib49","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib50","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib51","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib52","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hon.73_2629","article-title":"Predictive value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss group for clinical cancer research (SAKK)","volume":"37","author":"Moccia","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib54","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib55","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib56","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.002_bib57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib58","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2020.02.002_bib59","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3324\/haematol.2018.206177","article-title":"Liquid biopsy in lymphoma","volume":"104","author":"Rossi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.002_bib60","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","article-title":"Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy","volume":"126","author":"Zohren","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood-2018-99-115930","article-title":"Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the Phase III GALLIUM study of obinutuzumab- or rituximab-based immunochemotherapy in previously untreated follicular lymphoma patients","volume":"132","author":"Pott","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib62","article-title":"Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy","author":"Pulsoni","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib63","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib64","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib65","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib66","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib67","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.002_bib68","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2020.02.002_bib69","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","article-title":"Low serum Vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies","volume":"33","author":"Kelly","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.002_bib70","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1038\/bcj.2017.70","article-title":"Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma","volume":"7","author":"Tracy","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2020.02.002_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.17302","article-title":"Vitamin D and health outcomes: then came the randomized clinical trials","author":"Lucas","year":"2019","journal-title":"JAMA"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:24Z","timestamp":1760184864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889858820300277"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Biological Prognostic Factors in Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}